Innoviva Stock Price. Everything You Need To Know About The Innoviva Stock!
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 101 full-time employees. The company went IPO on 2004-10-05. The firm owns a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) collaboration agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI) and an inhaled corticosteroid (ICS), fluticasone furoate (FF). Its TRELEGY ELLIPTA is a once-daily combination medicine consisting of an ICS, long-acting muscarinic antagonist (LAMA) and LABA. Its portfolio also includes sulbactam-durlobactam (SUL-DUR). The company also provides GIAPREZA (angiotensin II) and XERAVA (eravacycline).
Innoviva Stock Price. Everything You Need To Know About The Innoviva Stock! performance
- Employees 101
- Company HQ Burlingame
- Website https://www.inva.com/
- INVA Asset Type Common Stock
- INVA Market Capitalization 944.7M
- Earnings Per Share 2.2
- Dividends Per Share None
- Dividend Date 2015-09-30
- Quarterly Earnings Growth -0.649
Innoviva is a compelling stock option for retail investors from Malaysia, Thailand, Indonesia, and Vietnam looking to diversify their investment portfolio. With Zorion’s user-friendly investment platform, investing in Innoviva has never been easier. As a global leader in the healthcare industry, Innoviva specializes in discovering and developing innovative therapies to improve patient care. With a strong focus on research and development, Innoviva aims to provide cutting-edge solutions that address critical unmet medical needs. By investing in Innoviva, retail investors can have a direct stake in the company’s growth and contribute to advancements in healthcare. Zorion provides valuable investment insights and recommendations to ensure informed decision-making. Explore Zorion’s resources and educational materials to enrich your investment knowledge and start investing in Innoviva today.
